Guggenheim downgraded Icosavax to Neutral from Buy without a price target. The analyst cites the pending AstraZeneca (AZN) takeover for the downgrade and believes AstraZeneca is the sole and final interested party in the company.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on ICVX:
- Icosavax just downgraded at Jefferies, here’s why
- Icosavax just downgraded at William Blair, here’s why
- M & A News: AstraZeneca’s (NASDAQ:AZN) $1.1B Bet on ICVX Sends Shares Soaring
- Icosavax announces interim results from IVX-A12 trial
- Icosavax to be acquired by AstraZeneca for $15.00 per share in cash, CVR